Imatinib 80 mg/mL Oral Sol.
| Product Overview | |
| Generic Name | Imatinib 80 mg/mL Oral Sol. | 
| Brand Name(s) | Gleevec | 
| Form | Oral Sol 80 mg/mL of 240 mL | 
| Strength | 80 mg/mL | 
| Therapeutic Class | Tyrosine-kinase inhibitor | 
| ATC Code | L01EA01 | 
| Manufacturing & Regulatory | |
| Manufacturer | Novartis | 
| Country | India/USA/EU | 
| GMP Compliance | WHO-GMP certified | 
| DMF/CEP | Type II/III | 
| COFEPRIS | Under Registration (2025) | 
| Free Sale Certificate | Yes | 
| Logistics & Export | |
| MOQ | 10 units | 
| Shelf Life | 24 months | 
| Storage | 20–25 °C | 
| Incoterms | EXW/FOB/CIF negotiable | 
| Lead Time | 7 to 10 Days | 
| Documentation | |
| Certificate of Analysis (COA) | Yes | 
| SDS | Upon Request | 
| CTD Summary | CTD from originator; generic use abbreviated formats | 
Description
This is the Oral Solution presentation of  80 mg/mL of 240mL Oral Sol.
Use and Indications for Imatinib: Imatinib is a tyrosine kinase inhibitor indicated for the treatment of chronic myeloid leukemia (CML), Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL), gastrointestinal stromal tumors (GIST), and other malignancies driven by BCR-ABL, KIT, or PDGFR mutations. It works by inhibiting abnormal tyrosine kinase signaling involved in cancer cell proliferation.
 
				